News and Notes from the Carcinoid Cancer Foundation, October 2021

Dr. Pamela Kunz Named Woman Oncologist of the YearPamela Kunz, MD_Yale Appointment 2020

Congratulations to NET expert Pamela Kunz, MD, who was named Woman Oncologist of the Year! Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief of GI Medical Oncology and Vice Chief, Diversity Equity and Inclusion, Medical Oncology. The Women Leaders in Oncology award honors a senior professional who is a respected individual in her field and who has modeled excellence in leadership. READ MORE

Second Generation Immunohistochemical Markers: Reflections from Clinical Implementation

This new article from pathologist Carl Christofer Juhlin, MD, PhD, of Karolinska Institutet in Sweden identifies second-generation neuroendocrine immunohistochemical markers.  These markers can help identify the site of primary neuroendocrine tumors as well as helping to ensure a proper diagnosis for NETs and poorly differentiated neuroendocrine carcinoma. Read more in this open access article here,

Second-Generation Neuroendocrine Markers

Chemotherapy in Neuroendocrine Tumors

Sharing a new review of the evolution/current role for chemotherapy in neuroendocrine tumors by NET experts Satya Das, MD of Vanderbilt University Medical Center in Tennessee;  Jonathan Strosberg, MD, and Taymeyah Al-Toubah, MPH, both of Moffitt Cancer Center in Florida. “Chemotherapy in Neuroendocrine Tumors” is part of a special issue published by Cancers on Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments. READ MORE

New Clinical Trial of Peptide Receptor Radionuclide Therapy with Lutathera in Adolescents

Advanced Accelerator Applications, a Novartis company, has announced a new clinical trial, NETTER-P, to study the safety and dosimetry of Lutathera in adolescent patients with gastroenteropancreatic NETs, pheochromocytoma, and paraganglioma.  In the United States the trial will be conducted at 5 locations: the University of Iowa Carver College of Medicine, the University of Kentucky, Cincinnati Children’s Hospital in Ohio, Children’s Hospital of Philadelphia in Pennsylvania, and Texas Children’s Hospital in Houston.  There are additional sites in Canada and Europe.  READ MORE at here NCT04711135.

NCCN Publishes New Guide for Small Cell Lung Cancer Patients

Lung neuroendocrine tumors, NCCN Small Cell Lung Cancer Guidelines_2

Did you know that small cell lung cancer (SCLC) is the most common type of pulmonary neuroendocrine tumor?  The NCCN, National Comprehensive Cancer Network, has just published Small Cell Lung Cancer, a new guide for patients.  CLICK HERE to download patient guidelines, including the SCLC Guidelines (2022) and Neuroendocrine Tumors Guidelines (2018).




Print Friendly, PDF & Email